The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Advances in immunotherapy for lymphoma
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, provides an overview of current developments in the field of immunotherapy in lymphoma. A lot of progress has been made in monoclonal antibodies, bispecific antibodies, as well as chimeric antigen receptor (CAR) T-cell therapies. Dr Hutchings additionally comments on looking forward to the next generation of immunotherapies, such as anti-CD20 IgM antibodies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
